相似文献
1
Targeted cancer stem cell therapies start with proper identification of the target.
Mol Cancer Res. 2010 Feb;8(2):291; author reply 291. doi: 10.1158/1541-7786.MCR-09-0505. Epub 2010 Feb 9.
2
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.
3
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
EMBO Rep. 2017 Jan;18(1):150-168. doi: 10.15252/embr.201642360. Epub 2016 Dec 19.
4
Proteasome inhibition and stress compromise the heart in chemotherapy.
Cardiovasc Res. 2008 Sep 1;79(4):547-8. doi: 10.1093/cvr/cvn191. Epub 2008 Jul 11.
5
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
Blood. 2009 Mar 26;113(13):3040-9. doi: 10.1182/blood-2008-08-172734. Epub 2009 Jan 22.
6
Neural stem cells and glioma stem-like cells respond differently to chemotherapeutic drugs: selectivity at the cellular level.
Neurosurgery. 2011 Jun;68(6):N21-2. doi: 10.1227/01.neu.0000398212.65736.e1.
7
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
J Cell Physiol. 2007 Aug;212(2):298-306. doi: 10.1002/jcp.21102.
8
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):222-5. doi: 10.1016/j.bbrc.2011.11.053. Epub 2011 Nov 19.
9
Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.
Int J Mol Sci. 2021 Oct 27;22(21):11633. doi: 10.3390/ijms222111633.
10
Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Exp Brain Res. 2023 Oct;241(10):2409-2418. doi: 10.1007/s00221-023-06693-8. Epub 2023 Aug 29.
引用本文的文献
1
Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling.
Nat Commun. 2015 Oct 15;6:8640. doi: 10.1038/ncomms9640.
2
Opportunities and challenges of radiotherapy for treating cancer.
Nat Rev Clin Oncol. 2015 Sep;12(9):527-40. doi: 10.1038/nrclinonc.2015.120. Epub 2015 Jun 30.
3
Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Mol Cancer. 2015 Mar 7;14:56. doi: 10.1186/s12943-015-0326-0.
4
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.
5
Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.
Mol Cancer. 2011 Sep 14;10:112. doi: 10.1186/1476-4598-10-112.
本文引用的文献
1
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Stem Cells. 2010 Jan;28(1):5-16. doi: 10.1002/stem.254.
2
z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response.
Mol Cancer Res. 2009 Nov;7(11):1822-34. doi: 10.1158/1541-7786.MCR-09-0225. Epub 2009 Oct 27.
3
In vivo imaging, tracking, and targeting of cancer stem cells.
J Natl Cancer Inst. 2009 Mar 4;101(5):350-9. doi: 10.1093/jnci/djn509. Epub 2009 Feb 24.
Zotero 插件